Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
AOD-9604 vs Dulaglutide (Trulicity)
An educational, source-based comparison of AOD-9604 and Dulaglutide (Trulicity) — how each peptide works, what it's researched for, and what to know before going deeper.
A modified 16-amino-acid fragment (177–191) of human growth hormone, engineered to retain the lipolytic activity of GH without its growth or insulin-resistance effects. Research suggests it stimulates lipolysis and inhibits lipogenesis.
- Obesity (clinical trials did not meet endpoints)
- Osteoarthritis / cartilage repair (current research direction)
- Localized adipose research
- • Not FDA-approved as a therapeutic.
- • Has GRAS status in some food contexts (Australia), not equivalent to drug approval.
Once-weekly GLP-1 agonist with cardiovascular benefit.
GLP-1 analog fused to a modified human IgG4 Fc fragment, giving a half-life that supports weekly dosing. Improves glycemia and reduces MACE in T2D.
- Type 2 diabetes
- Cardiovascular risk reduction in T2D
- • FDA-approved.
- • Boxed warning: thyroid C-cell tumors in rodents.
AOD-9604 vs Dulaglutide (Trulicity) — Key differences
- Class: AOD-9604 is classified as Metabolic · Lipolysis, while Dulaglutide (Trulicity) is GLP-1 Agonist · Metabolic.
- Primary research focus: AOD-9604 — obesity (clinical trials did not meet endpoints); Dulaglutide (Trulicity) — type 2 diabetes.
- Tag: Fat loss vs FDA-Approved · Metabolic.